Latest news
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - Business WireBusiness Wire · Mon, 10 Aug 2026 11:00:00 GMTAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Business WireBusiness Wire · Fri, 07 Aug 2026 20:30:00 GMTAbCellera Biologics Inc (8QQ.MU) stock price, news, quote and history - Yahoo Finance AustraliaYahoo Finance Australia · Thu, 06 Aug 2026 17:30:00 GMTAbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions - Business WireBusiness Wire · Wed, 29 Jul 2026 07:00:00 GMT